Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer

Lung Cancer（2022）

引用 8|浏览30

暂无评分

摘要

•Continued benefit at 3 years with nivolumab vs chemo in Asian patients with aNSCLC.•Nivolumab showed improvements in disease-related symptoms and overall health status.•Findings support long-term use of 2L nivolumab in Asian patients with aNSCLC.

查看译文

关键词

Advanced non-small cell lung cancer,PD-1 checkpoint inhibitor,Nivolumab,Patient-reported outcomes,Asian,Second-line treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要